Evidence map›Paper›PMID 40909313›Full record

ArticleIJU case reports2025

Locally Advanced Prostate Squamous Cell Carcinoma Diagnosed Using PET-CT and Treated With Robot-Assisted Radical Prostatectomy.

Masayuki Waki, Akira Fujisaki, Shunya Usami, Kei Muraoka, Yasuhiro Hakamata, Yuka Kanda, Kota Sugiura, Masashi Yoshida, Yoshiro Otsuki, Tatsuaki Yoneda

Abstract read
In one paragraph

Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masayuki WakiDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.ORCID https://orcid.org/0000-0003-3559-1907
Akira FujisakiDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Shunya UsamiDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Kei MuraokaDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.ORCID https://orcid.org/0009-0002-1297-186X
Yasuhiro HakamataDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Yuka KandaDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Kota SugiuraDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Masashi YoshidaDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Yoshiro OtsukiDepartment of Pathology Seirei Hamamatsu General Hospital Hamamatsu Japan.
Tatsuaki YonedaDepartment of Urology Seirei Hamamatsu General Hospital Hamamatsu Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Primary squamous cell carcinoma of the prostate accounts for < 1% of prostate cancers. Case Presentation: A 70-year-old man with no urinary symptoms and a normal prostate-specific antigen of 0.96 ng/mL was referred for abnormal prostate uptake on positron emission tomography-computed tomography. He was diagnosed with locally advanced squamous cell carcinoma of the prostate with lymph node metastasis. Robot-assisted radical prostatectomy and adjuvant chemoradiotherapy were administered. The patient remained in complete remission at 18 months postoperatively. Conclusion: Squamous cell carcinoma of the prostate should be suspected based on positron emission tomography-computed tomography prostate uptake. Robot-assisted radical prostatectomy may be feasible for locally advanced squamous cell carcinoma of the prostate; genetic profiling should be considered to identify targeted therapies.

Indexed as

genetic panel testingmultimodal treatmentPET‐CTRARPsquamous cell carcinoma of the prostate

Identifiers

PMID40909313
PMCPMC12408172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.